JP5235890B2 - 結晶性s−(−)−アムロジピンアジピン酸塩無水物およびその製造方法 - Google Patents
結晶性s−(−)−アムロジピンアジピン酸塩無水物およびその製造方法 Download PDFInfo
- Publication number
- JP5235890B2 JP5235890B2 JP2009534500A JP2009534500A JP5235890B2 JP 5235890 B2 JP5235890 B2 JP 5235890B2 JP 2009534500 A JP2009534500 A JP 2009534500A JP 2009534500 A JP2009534500 A JP 2009534500A JP 5235890 B2 JP5235890 B2 JP 5235890B2
- Authority
- JP
- Japan
- Prior art keywords
- amlodipine
- crystalline
- anhydride
- adipate anhydride
- amlodipine adipate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
S−(−)−アムロジピン13g(0.0316mol)をイソプロパノール173mLとエタノール87mLとの混合溶媒に加えて溶かした。ここにアジピン酸4.85g(1.05当量)を加え、25℃で2時間攪拌した後、生成された固体を濾過した。生成された固体をイソプロパノールとエタノール(2:1)の混合溶媒50mLで洗浄し、濾過した後、40℃で真空乾燥させた。その結果、S−(−)−アムロジピンアジピン酸塩無水物15.5gを白色の結晶性固体として得た(収率:91%、水分:0.15%)。
−元素分析:C26H35ClN2IN2O8[実測値(C:56.32、H:6.34、N:5.08、O:25.91)、理論値(C:56.26、H:6.36、N:5.05、O:25.94)]、
−融点:134〜136℃。
S−(−)−アムロジピン13g(0.0316mol)を蒸留水120mLに加えてスラリー化させた後、アジピン酸5g(1.05当量)を加えて攪拌した。完全に溶解した状態を維持していて、5時間攪拌すると、結晶が析出される。前記結晶を濾過して蒸留水50mLで洗浄した後、40℃で真空乾燥させてS−(−)−アムロジピン 16gを得た(収率:89%、水分:0.7%)。
−融点:134〜136℃。
米国特許第6,046,338号に開示されている方法によってS−(−)−アムロジピンを製造した。また、韓国公開特許公報第10−2005−37498号に開示されている方法によってS−(−)−アムロジピンを用いてS−(−)−アムロジピンベシレート2.5水和物を製造した。
韓国登録特許公報第10−0596369号に開示されている方法によってラセミアムロジピンを用いて結晶性ラセミアムロジピンアジピン酸塩無水物を製造した。
実施例1および実施例2で製造した結晶性S−(−)−アムロジピンアジピン酸塩無水物、比較実施例1で製造したS−(−)−アムロジピンベシレート2.5水和物、および比較実施例2で製造した結晶性ラセミアムロジピンアジピン酸塩無水物を25℃で様々な湿度条件(25%、60%、75%、95%)の下に含水量(K.F.水分%)を測定した。
実施例1で製造した結晶性S−(−)−アムロジピンアジピン酸塩無水物、比較実施例1で製造したS−(−)−アムロジピンベシレート2.5水和物、および比較実施例2で製造した結晶性ラセミアムロジピンアジピン酸塩無水物を25℃で様々なpH溶液条件の下に溶解度を測定した。
1.固体状態における熱安定性
実施例1で製造した結晶性S−(−)−アムロジピンアジピン酸塩無水物、比較実施例1で製造したS−(−)−アムロジピンベシレート2.5水和物、および比較実施例2で製造した結晶性ラセミアムロジピンアジピン酸塩無水物を有し、60℃で加速実験を行った。
−検出器:紫外線吸光度(測定波長237nm)
−カラム:オクタデシルシリカゲルC18(4.6mm×150mm、5μm)
−移動相:リン酸二水素カリウムモノベイシック(0.03M):メタノール=4:6(体積)
−流速:1.5mL/min。
水溶液状態で熱安定性を調べるために、実施例1で製造した結晶性S−(−)−アムロジピンアジピン酸塩無水物、比較実施例1で製造したS−(−)−アムロジピンベシレート2.5水和物、および比較実施例2で製造した結晶性ラセミアムロジピンアジピン酸塩無水物をそれぞれ蒸留水に溶かした後、25℃で遮光して4週間保管して含量変化を観察した。この際、前記固体状態における熱安定性試験に使用したHPLC分析条件と同一の方法で含量変化を観察した。
実施例1で製造した結晶性S−(−)−アムロジピンアジピン酸塩無水物、比較実施例1で製造したS−(−)−アムロジピンベシレート2.5水和物、および比較実施例2で製造した結晶性ラセミアムロジピンアジピン酸塩無水物を25℃で、ICHガイドラインに適した光安定性チャンバー(photostability chamber)で光源に露出させたままで4週間保管した。光安定性を測定するために、含量(HPLC)の変化を測定した。HPLC分析条件は熱安定性の観察条件と同様にした。
Claims (4)
- 下記化学式1で表される、結晶性S−(−)−アムロジピンアジピン酸塩無水物:
- 不活性溶媒中でS−(−)−アムロジピンとアジピン酸とを反応させて下記化学式1の結晶性S−(−)−アムロジピンアジピン酸塩無水物を得ることを特徴とする、結晶性S−(−)−アムロジピンアジピン酸塩無水物の製造方法:
前記不活性溶媒は、エタノール、イソプロパノールおよびエタノールとイソプロパノールとの混合溶媒よりなる群から選ばれた少なくとも1種であり、
前記結晶性S−(−)−アムロジピンアジピン酸塩無水物は、9.6°、11.0°、13.54°、14.52°、14.58°、15.30°、17.48°、17.92°、17.98°、18.02°、19.34°、21.14°、22.14°、23.20°、24.26°、25.32°、26.60°、27.14°、27.26°、28.26°、28.62°、30.62°、31.96°、32.02°、33.06°、35.36°、35.98°、36.04°、37.42°、および44.68°の回折角度で回折X線ピークを有し、融点が134〜136℃である。 - 有効成分として請求項1の結晶性S−(−)−アムロジピンアジピン酸塩無水物を含む、心臓血管系疾患の予防または治療用薬学組成物。
- 前記組成物は錠剤、カプセル、顆粒、丸薬または注射剤に製剤化されることを特徴とする、請求項3に記載の心臓血管系疾患の予防または治療用薬学組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060106185A KR100830003B1 (ko) | 2006-10-31 | 2006-10-31 | 결정성 s-(-)-암로디핀 아디핀산 염 무수물 및 이의 제조방법 |
KR10-2006-0106185 | 2006-10-31 | ||
PCT/KR2007/005335 WO2008054096A1 (en) | 2006-10-31 | 2007-10-26 | Crystalline s-(-)-amlodipine adipic acid salt anhydrous and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010508264A JP2010508264A (ja) | 2010-03-18 |
JP5235890B2 true JP5235890B2 (ja) | 2013-07-10 |
Family
ID=39344416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009534500A Expired - Fee Related JP5235890B2 (ja) | 2006-10-31 | 2007-10-26 | 結晶性s−(−)−アムロジピンアジピン酸塩無水物およびその製造方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8362263B2 (ja) |
EP (1) | EP2077994A4 (ja) |
JP (1) | JP5235890B2 (ja) |
KR (1) | KR100830003B1 (ja) |
CN (1) | CN101528696B (ja) |
WO (1) | WO2008054096A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1397912B1 (it) * | 2010-01-28 | 2013-02-04 | Chemi Spa | Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato. |
US11084558B2 (en) | 2018-07-03 | 2021-08-10 | Excipio Energy, Inc. | Integrated offshore renewable energy floating platform |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK161312C (da) | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
US6057344A (en) * | 1991-11-26 | 2000-05-02 | Sepracor, Inc. | Methods for treating hypertension, and angina using optically pure (-) amlodipine |
GB9317773D0 (en) * | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
GB9405833D0 (en) * | 1994-03-24 | 1994-05-11 | Pfizer Ltd | Separation of the enantiomers of amlodipine |
CN1163485C (zh) | 2000-09-15 | 2004-08-25 | 付俊昌 | 氨氯地平系列盐及其制备方法和用途 |
KR100452491B1 (ko) * | 2001-03-29 | 2004-10-12 | 한미약품 주식회사 | 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법 |
MXPA03008801A (es) * | 2001-03-29 | 2004-02-18 | Schering Corp | Aril oxima-piperazinas utiles como antagonistas de ccr5. |
CN1152013C (zh) | 2001-11-22 | 2004-06-02 | 张喜田 | 一类左旋氨氯地平盐的水合物及其制剂 |
KR100515294B1 (ko) | 2002-09-11 | 2005-09-15 | 한림제약(주) | 에스-(-)-암로디핀 니코티네이트 결정성 2수화물 |
CN100420673C (zh) * | 2002-09-11 | 2008-09-24 | 韩林制药株式会社 | S-(-)-氨氯地平烟酸盐及其制备方法 |
WO2004026834A1 (en) * | 2002-09-19 | 2004-04-01 | Cj Corporation | Crystalline organic acid salt of amlodipine |
KR100596369B1 (ko) | 2002-09-19 | 2006-07-03 | 씨제이 주식회사 | 결정형의 암로디핀 유기산염 |
KR100841409B1 (ko) * | 2003-12-16 | 2008-06-25 | 에스케이케미칼주식회사 | 암로디핀 겐티세이트 염과 이의 제조방법 |
WO2005089353A2 (en) * | 2004-03-16 | 2005-09-29 | Sepracor Inc. | (s)-amlodipine malate |
KR100843400B1 (ko) * | 2006-11-14 | 2008-07-04 | 씨제이제일제당 (주) | 결정성 s-(-)-암로디핀 말레익산 염 무수물 및 이의제조방법 |
KR100843401B1 (ko) * | 2006-12-04 | 2008-07-04 | 씨제이제일제당 (주) | 결정성 s-(-)-암로디핀 캠실레이트 무수물 및 이의제조방법 |
KR100840069B1 (ko) * | 2007-01-23 | 2008-06-20 | 씨제이제일제당 (주) | 결정성 s-(-)-암로디핀 오로테이트 무수물 및 이의제조방법 |
-
2006
- 2006-10-31 KR KR1020060106185A patent/KR100830003B1/ko not_active IP Right Cessation
-
2007
- 2007-10-26 CN CN2007800396469A patent/CN101528696B/zh not_active Expired - Fee Related
- 2007-10-26 EP EP07833643A patent/EP2077994A4/en not_active Withdrawn
- 2007-10-26 JP JP2009534500A patent/JP5235890B2/ja not_active Expired - Fee Related
- 2007-10-26 US US12/447,530 patent/US8362263B2/en not_active Expired - Fee Related
- 2007-10-26 WO PCT/KR2007/005335 patent/WO2008054096A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US8362263B2 (en) | 2013-01-29 |
CN101528696A (zh) | 2009-09-09 |
US20100069642A1 (en) | 2010-03-18 |
CN101528696B (zh) | 2012-05-16 |
JP2010508264A (ja) | 2010-03-18 |
EP2077994A4 (en) | 2010-12-15 |
WO2008054096A1 (en) | 2008-05-08 |
EP2077994A1 (en) | 2009-07-15 |
KR20080038795A (ko) | 2008-05-07 |
KR100830003B1 (ko) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7579475B2 (en) | S-(-)-amlodipine nicotinate and process for the preparation thereof | |
JP4188088B2 (ja) | 新規なアムロジピンカンファースルホン酸塩及びその製造方法 | |
KR100843400B1 (ko) | 결정성 s-(-)-암로디핀 말레익산 염 무수물 및 이의제조방법 | |
JP4287752B2 (ja) | アムロジピンニコチネート及びその製造方法 | |
KR20060080818A (ko) | 시부트라민의 술폰산염 | |
JP5235890B2 (ja) | 結晶性s−(−)−アムロジピンアジピン酸塩無水物およびその製造方法 | |
TW200900392A (en) | Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same | |
KR100843401B1 (ko) | 결정성 s-(-)-암로디핀 캠실레이트 무수물 및 이의제조방법 | |
CA2433190C (en) | Amlodipine hemimaleate | |
MXPA03005886A (es) | Derivado de aspartato de amlodipina como antagonista del canal de calcio. | |
JP4740875B2 (ja) | アムロジピンのゲンチシン酸塩及びその製造方法 | |
KR100840069B1 (ko) | 결정성 s-(-)-암로디핀 오로테이트 무수물 및 이의제조방법 | |
KR100879972B1 (ko) | 결정형의 암로디핀 유기산염 | |
AU2001100436A4 (en) | Amlodipine hemimaleate | |
AU2001100435A4 (en) | Amlodipine fumarate | |
KR20090005271A (ko) | 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
SI21066A2 (sl) | Amlodipin fumarat | |
WO2004072036A1 (en) | Novel amlodipine cyclamate salt and a preparation method thereof | |
CZ12613U1 (cs) | Chemická sloučenina amlodipinaspartát a farmaceutický prostředek |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120529 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120823 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121002 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121225 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130131 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130312 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130326 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160405 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |